A LinkedIn post from Saluda Medical highlights physician feedback and clinical data on the company’s Evoke System for spinal cord stimulation in chronic pain management. According to the post, Dr. Johnathan Goree reports that his Evoke patients are not requiring reprogramming every six months, which he suggests had been common with other devices.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further notes that study participants averaged roughly one reprogramming visit after 12 months of therapy, while real‑world patients reportedly reached zero reprogramming visits by 12 months. These data were presented at ASPN 2025 in a talk titled “Minimal SCS Reprogramming in Study and Real-World Clinical Practice Settings Using the Evoke System,” with the physician identified as a paid consultant.
For investors, the emphasis on reduced reprogramming demand suggests potential workflow advantages for clinicians and lower maintenance burden for patients, which could support differentiated positioning versus competing spinal cord stimulation systems. If validated broadly, such outcomes may strengthen Evoke’s value proposition in terms of clinic efficiency and long‑term care costs.
The post also reiterates that the Evoke System is indicated as an aid in the management of chronic intractable pain of the trunk and limbs, underscoring Saluda Medical’s focus on the chronic pain segment. Continued visibility at specialty meetings like ASPN 2025 may help the company deepen relationships with pain specialists and expand adoption, though commercial impact will depend on reimbursement dynamics, competitive responses, and real‑world performance beyond early data sets.